Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Therapix Biosciences Ltd ADR TRPXY

Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

OTCPK:TRPXY - Post Discussion

Therapix Biosciences Ltd ADR > stopped out today
View:
Post by edmed on Mar 28, 2019 11:32am

stopped out today

I won't be back
the whole thing has been very disappointing
edmed
Comment by Fundy13 on Mar 28, 2019 12:48pm
I agree, they would have been better off accepting reduced terms from FSD Pharma then doing this bad deal.  Even if they took a buyout at 50% of the original $48million offer that would be double what they just sold shares for. They basically just valued themselves at $12million
Comment by Mining_Engineer_UBC on Mar 28, 2019 12:53pm
I feel your pain edmed. And its an act of courage to sell at what I'm assuming is a loss. For others still holding TRPX I will say that although this financing deal is not on the greatest of terms, it does obviously buy us some time to further advance our research and hopefully line up a merger/acquisition deal. In that sense this news reducing the risk profile in the near term as the risk of ...more  
Comment by Fundy13 on Mar 28, 2019 1:43pm
I knew financing was a good possibility and I knew the stock price woudl likely drop if that happened.  What has surprised me is how big a difference in financing this time compared to last.  They were just able to borrow at 5% with convertable debentures less then 6 months ago and now they are selling shares at $3.50 which is about a 20% discount to the 30 day moving average and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities